moatshark My

All holdings

Diamedica Therapeutics

DMAC

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$24.3m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$7.04
+4.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+42.0%Q3 ’24
+29.6%Q4 ’24
-30.2%Q1 ’25
+2.9%Q2 ’25
+38.4%Q3 ’25
+47.5%Q4 ’25
-14.9%Q1 ’26
+4.0%Q2 ’26
Q3 ’24: +42.0%; Q4 ’24: +29.6%; Q1 ’25: -30.2%; Q2 ’25: +2.9%; Q3 ’25: +38.4%; Q4 ’25: +47.5%; Q1 ’26: -14.9%; Q2 ’26: +4.0%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Diamedica Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Diamedica Therapeutics
Omega Family Office (Leon Cooperman)0.7%$24.3m$24.3mAdded +71%23 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector
Health care · Pharmaceutical Preparations
Financial year ends
31 December
Shares outstanding
54m at 3 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

Diamedica Therapeutics revenue and net income by year
YearRevenueNet income
2025–−$32.8m
2024–−$24.4m
2023–−$19.4m
2022–−$13.7m
2021–−$13.6m
2020–−$12.3m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.